STOCK TITAN

Vera Therapeutics (VERA) Stock Price, News & Analysis

VERA NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
36 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+13.3% close of November 26, 2025
1-year change
-1% closing prices, November 13, 2025 to November 13, 2026
1-month change
+4.9% closing prices, October 13, 2026 to November 13, 2026

Company Description

Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological and autoimmune diseases. The company describes its mission as advancing treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ work centers on B-cell biology and autoantibody-driven conditions, with programs that address kidney and transplant-related diseases where unmet medical need remains high.

The company’s lead product candidate is atacicept, an investigational recombinant fusion protein self-administered at home as a once-weekly subcutaneous injection. Atacicept blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), cytokines that stimulate B cells and plasma cells to produce autoantibodies associated with certain autoimmune diseases. Vera Therapeutics is developing atacicept for immunoglobulin A nephropathy (IgAN), a serious and progressive autoimmune kidney disease, and is also evaluating its potential in lupus nephritis and other autoimmune kidney diseases.

According to company disclosures, atacicept has received U.S. FDA Breakthrough Therapy Designation for the treatment of IgAN. Vera Therapeutics submitted a Biologics License Application (BLA) for atacicept for adults with IgAN through the FDA’s Accelerated Approval Program, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN, and could be offered as an autoinjector for at-home self-administration.

The atacicept clinical program in IgAN includes the ORIGIN Phase 2b trial and the ongoing ORIGIN 3 Phase 3 trial. Company reports state that ORIGIN Phase 2b met its primary and key secondary endpoints, showing statistically significant and clinically meaningful reductions in proteinuria and stabilization of estimated glomerular filtration rate (eGFR) versus placebo through 36 weeks, with further improvements in Gd-IgA1, hematuria, and proteinuria through 96 weeks. ORIGIN 3 is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial in adults with IgAN. A prespecified 36-week interim analysis met the primary endpoint of reduction in proteinuria, with a reported 46% reduction from baseline and a 42% reduction versus placebo in 24-hour urine protein-to-creatinine ratio. Across the ORIGIN program, the safety profile of atacicept is described as favorable and comparable to placebo.

Beyond the core IgAN program, Vera Therapeutics is evaluating atacicept in additional settings where reduction of autoantibodies may be clinically meaningful. These include expanded IgAN populations and other autoimmune kidney diseases such as anti-PLA2R positive primary membranous nephropathy and anti-nephrin positive focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), as described in the company’s PIONEER trial. The ORIGIN Extend study provides extended access to atacicept for ORIGIN participants and is designed to capture longer-term safety and efficacy data until potential commercial availability in relevant regions.

Vera Therapeutics also holds an exclusive license agreement with Stanford University for VT-109, described as a novel, next-generation fusion protein targeting BAFF and APRIL. The company characterizes VT-109 as having wide therapeutic potential across the spectrum of B-cell–mediated diseases, reflecting a broader strategic focus on B-cell and autoantibody pathways beyond a single indication. VT-109 remains an investigational asset within Vera Therapeutics’ pipeline.

In addition to its BAFF/APRIL-targeting programs, Vera Therapeutics is developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus. BK virus infection can have serious consequences in kidney transplant recipients, and Vera Therapeutics’ disclosures emphasize the potential impact of an effective neutralizing antibody in this setting. The company states that it retains all global developmental and commercial rights to atacicept, VT-109, and MAU868.

Vera Therapeutics is based in Brisbane, California, and its Class A common stock trades on The Nasdaq Stock Market LLC under the symbol VERA, as indicated in its SEC filings. As a late clinical-stage biotechnology issuer, the company regularly uses public offerings and at-the-market sales agreements to support its development activities, as reflected in its Form 8-K filings describing underwritten offerings of Class A common stock and a sales agreement with TD Securities (USA) LLC. These filings also highlight the company’s use of inducement equity awards under a 2024 Inducement Plan to attract new employees, consistent with Nasdaq Listing Rule 5635(c)(4).

Vera Therapeutics communicates clinical and regulatory milestones through press releases and SEC reports, including data presentations at major medical meetings such as the American Society of Nephrology Kidney Week and publications in peer-reviewed journals such as The New England Journal of Medicine. The company also participates in healthcare and investor conferences, where its management team presents updates on the atacicept program, broader pipeline, and corporate strategy.

Business focus and development model

Vera Therapeutics describes itself as a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases. Its development model centers on:

  • Targeting the source of disease by modulating B-cell activity and autoantibody production through BAFF and APRIL inhibition.
  • Advancing atacicept through Phase 2b and Phase 3 clinical programs in IgAN and other autoimmune kidney diseases.
  • Building a pipeline of B-cell–focused biologics, including VT-109 under an exclusive license from Stanford University.
  • Developing MAU868 to address BK virus infection in kidney transplant recipients.
  • Maintaining global developmental and commercial rights to its key product candidates.

Through these activities, Vera Therapeutics positions itself within the biotechnology sector as a company concentrating on immunology and nephrology, with an emphasis on autoantibody-driven disease mechanisms.

Key programs and indications

  • Atacicept in IgA nephropathy (IgAN): Investigational fusion protein targeting BAFF and APRIL, developed as a once-weekly subcutaneous injection for at-home self-administration. Supported by Phase 2b and Phase 3 ORIGIN trial data, with a BLA under Priority Review by the U.S. FDA for adults with IgAN.
  • Atacicept in other autoimmune kidney diseases: Evaluation in expanded IgAN populations and conditions such as lupus nephritis, primary membranous nephropathy, FSGS, and MCD, where autoantibody reduction may be clinically relevant.
  • VT-109: Next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, with stated potential across B-cell–mediated diseases.
  • MAU868: Monoclonal antibody designed to neutralize BK virus infection, which can have serious consequences in kidney transplant recipients.

Regulatory and clinical milestones

From the information provided, notable milestones for Vera Therapeutics and atacicept include:

  • FDA Breakthrough Therapy Designation for atacicept in IgAN.
  • Submission of a BLA for atacicept for adults with IgAN via the Accelerated Approval Program.
  • FDA Priority Review of the BLA with a specified PDUFA target action date.
  • Positive interim results from the ORIGIN 3 Phase 3 trial in IgAN, with statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo.
  • Presentation of ORIGIN Phase 3 data at the American Society of Nephrology Kidney Week and simultaneous publication in The New England Journal of Medicine.

Stock and corporate governance

Vera Therapeutics’ Class A common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Stock Market LLC under the symbol VERA, as reflected in multiple Form 8-K filings. The company’s board of directors oversees corporate governance, including the appointment of directors and committee members. For example, an 8-K dated November 26, 2025 reports the appointment of James R. Meyers as a Class II director and member of the Audit Committee, along with related equity compensation under the company’s non-employee director compensation policy.

Vera Therapeutics also reports changes in executive roles and material agreements through its SEC filings. An 8-K dated December 16, 2025 notes that the company’s Chief Legal Officer will no longer serve in that role as of December 24, 2025. Another 8-K dated August 5, 2025 describes entry into a Sales Agreement with TD Securities (USA) LLC for potential at-the-market offerings of Class A common stock, replacing a prior sales agreement.

Location and regulatory reporting

SEC filings list Vera Therapeutics’ principal offices in Brisbane, California. The company files current reports on Form 8-K to disclose material events such as clinical data announcements, financing transactions, sales agreements, and changes in directors or officers. These filings, together with press releases, provide investors with ongoing information about the company’s development programs and corporate activities.

Stock Performance

$27.31
-2.81%
-0.79
Pre-marketLast updated: November 16, 2026 at 07:31
-1%
Performance 1 year

Vera Therapeutics (VERA) closed at $28.10 on November 13, 2026. Over the past 12 months, the price has lost 1.0%.

See what a $1,000 investment in VERA would be worth today

Average down calculator for VERA

VERA Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Vera Therapeutics has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 7 with negative movement. Key topics include earnings, earnings date, conferences. View all VERA news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
37,000
Shares Sold
2
Transactions
Most Recent Transaction
Fordyce Marshall (PRESIDENT AND CEO) sold 18,500 shares @ $37.00 on September 15, 2026

Insider selling at Vera Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Vera Therapeutics reported operating income of -$315.5M in FY2025, and net income was -$299.6M. Diluted earnings per share stood at -$4.66. The company generated -$241.1M in operating cash flow. The current ratio was 13.64, measuring current assets divided by current liabilities.

-$299.6M
Net Income (FY2025)
-$241.1M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

NOV
20
November 20, 2026 - November 20, 2029 Corporate

RSU annual vesting schedule

21,000 RSUs vest 25% on each anniversary of 2025-11-20 (four years)
DEC
02
December 2, 2026 - December 2, 2029 Corporate

Stock option vesting period

42,000 options vest (25% after 1 year then monthly over 36 months)
Q1
2027
Q1 2027 Clinical

Clinical readout Q1 2027

Clinical readout expected in Q1 2027 from Vera’s clinical program; company will provide timing, presentation venue and data release plans when available.
Q1
2027
Q1 2027 Regulatory

EU marketing application

Planned European marketing application for TRUTAKNA to be submitted in Q1 2027 to pursue EU regulatory approval.
YEAR
2027
2027 Clinical

2-year ORIGIN 3 data

2-year ORIGIN 3 trial data readout
YEAR
2027
2027 Clinical

ORIGIN 3 eGFR results

ORIGIN 3 two-year eGFR results expected
YEAR
2027
2027 Clinical

Phase 3 trial completion

Expected completion of Phase 3 ORIGIN 3 trial assessing eGFR
YEAR
2027
2027 Clinical

ORIGIN 3 final results

Final results of ORIGIN 3 Phase 3 trial expected
YEAR
2027
2027 Regulatory

Potential full approval

Potential full FDA approval in 2027 if sBLA successful; material impact on commercialization and revenues.
JAN
05
January 5, 2027 Corporate

Options 25% vest

25% of 228,750 options vest (one-year cliff) for 18 new employees
FEB
02
February 2, 2027 Corporate

Options 25% cliff vest

11,500 non‑qualified options granted; 25% vests after one year; subject to service
FEB
20
February 20, 2027 Corporate

RSUs 25% vest

25% of 116,000 RSUs vest (first anniversary) for 18 new employees
MAR
03
March 3, 2027 Corporate

25% cliff vesting

25% one-year cliff vesting of inducement awards granted 2026-03-03; 46,000 options, 25,875 RSUs
MAR
03
March 3, 2027 - March 3, 2030 Corporate

Monthly vesting period

Remaining 75% vests monthly through four-year schedule; potential impact on share dilution
MAR
23
March 23, 2027 - March 23, 2030 Corporate

Option vesting schedule

56,850 options vest: 25% at 2027-03-23, then monthly over next 36 months
YEAR
2027
2027 Regulatory

Full FDA approval

Potential full FDA approval decision for TRUTAKNA (submission Nov 3); decision expected mid-2027, subject to FDA review.
MAY
04
May 4, 2027 Corporate

Options 25% vest

25% of 40,250 non-qualified stock options vest May 4, 2027 at $35.51 exercise; remaining monthly over 36 months.
MAY
04
May 4, 2027 - May 4, 2030 Corporate

Options monthly vesting period

Monthly vesting of remaining 75% of 40,250 options runs from 2027-05-04 through 2030-05-04; exercise price $35.51.
MAY
20
May 20, 2027 Corporate

RSU 25% vesting

25% of 42,403 RSUs vest (second annual RSU tranche)
AUG
20
August 20, 2027 Corporate

RSU first vesting

First 25% of RSUs (for employees with 2026-08-20 start) vest on 2027-08-20; may result in share delivery or market selling.
SEP
01
September 1, 2027 Corporate

Option first vesting

25% of inducement stock options granted Sept 1, 2026 vest one year later on 2027-09-01; potential share issuance or sales impact.
NOV
20
November 20, 2027 Corporate

RSU first vesting

First 25% of RSUs (for employees with 2026-11-20 start) vest on 2027-11-20; could lead to share issuance or insider selling.
NOV
20
November 20, 2027 Corporate

RSU annual vesting

25% of 7,450 RSUs vest on Nov 20, 2027 per inducement awards; continued service required; potential dilution impact.
FEB
20
February 20, 2028 Corporate

RSUs 25% vest

Second RSU anniversary vesting (25% of 5,750 RSUs); subject to continued service
MAY
20
May 20, 2028 Corporate

RSU 25% vesting

25% of 42,403 RSUs vest (third annual RSU tranche)
NOV
20
November 20, 2028 Corporate

RSU annual vesting

25% of 7,450 RSUs vest on Nov 20, 2028 per inducement awards; continued service required; potential dilution impact.
FEB
20
February 20, 2029 Corporate

RSUs 25% vest

Third RSU anniversary vesting (25% of 5,750 RSUs); subject to continued service
MAY
20
May 20, 2029 Corporate

RSU 25% vesting

Final 25% of 42,403 RSUs vest (fourth anniversary)
NOV
20
November 20, 2029 Corporate

RSU annual vesting

25% of 7,450 RSUs vest on Nov 20, 2029 per inducement awards; continued service required; potential dilution impact.
JAN
05
January 5, 2030 Corporate

Options fully vested

Remaining options vest monthly after cliff; fully vested by this date
FEB
02
February 2, 2030 Corporate

Options fully vested

Remaining options vest monthly after cliff; full vest completes four years post-grant
FEB
20
February 20, 2030 Corporate

RSUs fully vested

Final 25% RSU tranche vests; full vesting of 116,000 RSUs
FEB
20
February 20, 2030 Corporate

RSUs final 25% vest

Final RSU anniversary vesting (last 25% of 5,750 RSUs); subject to continued service
JUL
06
July 6, 2030 Corporate

Equity awards final vesting

32,100 options and 16,050 RSUs under 2024 Inducement Plan (granted 2026-07-06) vest over four years; final vest 2030-07-06.
SEP
01
September 1, 2030 Corporate

Options full vesting

Remaining inducement options granted 2026-09-01 fully vest by 2030-09-01 after 4-year schedule; long-term potential share issuance.
NOV
20
November 20, 2030 Corporate

RSU annual vesting

25% of 7,450 RSUs vest on Nov 20, 2030 per inducement awards; continued service required; potential dilution impact.

Vera Therapeutics has 36 upcoming scheduled events. The next event, "RSU annual vesting schedule", is scheduled for November 20, 2026 (in 4 days). Investors can track these dates to stay informed about potential catalysts that may affect the VERA stock price.

Short Interest History

Last 12 Months

Short interest in Vera Therapeutics (VERA) currently stands at 12.1 million shares, down 10.6% from the previous reporting period, representing 17.1% of the float. Since November 2025, short interest has increased by 12.2%.

Days to Cover History

Last 12 Months

Days to cover for Vera Therapeutics (VERA) currently stands at 8.5 days, up 18.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 4.0 to 11.2 days.

VERA Company Profile & Sector Positioning

Vera Therapeutics (VERA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing VERA often look at related companies in the same sector, including Immunome, Inc. (IMNM), Aurinia Pharmaceuticals Inc (AUPH), Biohaven Ltd. (BHVN), Septerna, Inc. (SEPN), and Celldex Therapeutics, Inc (CLDX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate VERA's relative position within its industry.

Frequently Asked Questions

The current stock price of Vera Therapeutics (VERA) is $27.31 in pre-market trading as of November 16, 2026.

The market cap of Vera Therapeutics (VERA) is approximately $2.0B. Learn more about what market capitalization means .

The FY2025 net income of Vera Therapeutics (VERA) is -$299.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Vera Therapeutics (VERA) is -$4.66 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Vera Therapeutics (VERA) is -$241.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Vera Therapeutics (VERA), current assets divided by current liabilities, was 13.64 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Vera Therapeutics (VERA) is -$315.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Vera Therapeutics, Inc. is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Its lead product candidate is atacicept, an investigational fusion protein targeting BAFF and APRIL for autoimmune kidney diseases such as immunoglobulin A nephropathy (IgAN) and lupus nephritis.

Atacicept is an investigational recombinant fusion protein that contains the soluble TACI receptor and binds to the cytokines BAFF and APRIL. These cytokines promote B-cell survival and autoantibody production associated with IgAN, lupus nephritis, and other autoimmune kidney diseases. Vera Therapeutics is developing atacicept as a once-weekly subcutaneous injection for at-home self-administration, supported by Phase 2b and Phase 3 ORIGIN trial data in IgAN.

Vera Therapeutics reports that atacicept has received U.S. FDA Breakthrough Therapy Designation for the treatment of immunoglobulin A nephropathy (IgAN). The company has submitted a Biologics License Application for atacicept for adults with IgAN through the FDA’s Accelerated Approval Program, and the FDA has granted Priority Review with a specified PDUFA target action date.

ORIGIN 3 is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial of atacicept in adults with IgA nephropathy. Participants are randomized to atacicept or placebo as a once-weekly subcutaneous injection. A prespecified 36-week interim analysis met the primary endpoint of reduction in proteinuria, with a reported 46% reduction from baseline and 42% reduction versus placebo in 24-hour urine protein-to-creatinine ratio, and a safety profile described as comparable to placebo.

Vera Therapeutics states that beyond IgAN, it is evaluating additional diseases where reduction of autoantibodies by atacicept may be clinically meaningful. These include expanded IgAN populations, lupus nephritis, anti-PLA2R positive primary membranous nephropathy, and anti-nephrin positive focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), as described in the PIONEER trial.

VT-109 is described by Vera Therapeutics as a novel, next-generation fusion protein targeting BAFF and APRIL. The company holds an exclusive license agreement with Stanford University for VT-109 and characterizes it as having wide therapeutic potential across the spectrum of B-cell–mediated diseases.

MAU868 is a monoclonal antibody in development by Vera Therapeutics that is designed to neutralize infection with BK virus. The company notes that BK virus infection can have serious consequences in kidney transplant recipients, and MAU868 is aimed at this clinical setting.

Vera Therapeutics’ SEC filings list its principal offices in Brisbane, California. The company’s Class A common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker symbol VERA.

According to company disclosures, Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. VT-109 is held under an exclusive license agreement with Stanford University, while atacicept and MAU868 are being developed directly by the company.

Vera Therapeutics communicates updates through press releases, participation in healthcare and investor conferences, and SEC filings such as Form 8-K. These communications cover clinical trial results, regulatory milestones, financing transactions, sales agreements, and changes in directors or officers.